U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.20 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.65 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +0.19 (+0.29%)
     
  • Gold

    1,698.20
    -0.30 (-0.02%)
     
  • Silver

    25.30
    +0.01 (+0.03%)
     
  • EUR/USD

    1.1919
    -0.0060 (-0.50%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3817
    -0.0077 (-0.55%)
     
  • USD/JPY

    108.3350
    +0.3590 (+0.33%)
     
  • BTC-USD

    50,108.39
    +1,611.70 (+3.32%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Amarin Corp: Q3 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Amarin Corp (NASDAQ: AMRN) fell 0.2% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 100.00% over the past year to ($0.02), which missed the estimate of $0.01.

Revenue of $156,499,000 up by 39.22% year over year, which beat the estimate of $154,630,000.

Outlook

Amarin Corp hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 05, 2020

View more earnings on AMRN

Time: 07:30 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2037/38230

Recent Stock Performance

Company's 52-week high was at $26.12

Company's 52-week low was at $3.36

Price action over last quarter: down 27.41%

Company Overview

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.